trabecular follicular adenocarcinoma

Based on the provided context, it appears that there are limited specific details regarding the drug treatment for trabecular follicular adenocarcinoma. However, I can provide some general information related to the treatment of thyroid cancer.

• Multikinase inhibitors: The multikinase inhibitors sorafenib and lenvatinib have been approved as a first-line therapy for locally advanced or metastatic RAI-refractory DTC and PDTC [4]. However, it is unclear if these drugs are specifically used to treat trabecular follicular adenocarcinoma.
• Vandetanib: Vandetanib has been approved by the FDA for the treatment of advanced and progressive and/or symptomatic MTC. However, its use in treating follicular thyroid cancer is not explicitly mentioned [1].
• Targeted therapy: Targeted therapy (drugs that destroy specific cancer cells) may be used to treat thyroid cancer, including follicular thyroid cancer [11]. However, the specifics of this treatment for trabecular follicular adenocarcinoma are unclear.

It's worth noting that the treatment of thyroid cancer can vary depending on the stage and type of cancer. If you're looking for specific information on drug treatment for trabecular follicular adenocarcinoma, it may be helpful to consult a medical professional or a reliable health resource.

References:

[1] Vandetanib is the first medication approved by the FDA for the treatment of advanced and progressive and/or symptomatic MTC. [Context 1]

[4] The multikinase-inhibitors (MKIs) sorafenib and lenvatinib are approved as a first-line therapy for locally advanced or metastatic RAI-refractory DTC and PDTC. [Context 4]

[11] Targeted therapy (drugs that destroy specific cancer cells). Thyroid hormone therapy. Are there side effects of follicular thyroid cancer treatment? Cancer treatments can cause different side effects. You might have: Diarrhea. Loss of appetite. Fatigue. Hair loss. Nausea and vomiting. Speech and swallowing problems. [Context 11]